Alpha-fetoprotein – tumor marker Medical Devices – Page 1

Below is a list of medical devices and their corresponding complexity (CLIA WAIVED, MODERATE, or HIGH) when testing for Alpha-fetoprotein – tumor marker. Note that there may be additional pages of medical devices which test for Alpha-fetoprotein – tumor marker to choose from located at the bottom of the list.

Medical Device – Page 1	COMPLEXITY
Abbott AFP EIA Analyte: Alpha-fetoprotein – tumor marker	HIGH
Abbott ARCHITECT i1000SR System Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Abbott ARCHITECT i2000 System Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Abbott ARCHITECT i2000SR System Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Abbott ARCHITECT i2000SR System Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Abbott AxSYM Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Abbott COMMANDER System Analyte: Alpha-fetoprotein – tumor marker	HIGH
Abbott IMx Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Amersham Amerlex Analyte: Alpha-fetoprotein – tumor marker	HIGH
BAYER ACS:180 Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Bayer ADVIA Centaur CP Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Bayer ADVIA IMS Analyte: Alpha-fetoprotein – tumor marker	MODERATE
BAYER ADVIA:CENTAUR Analyte: Alpha-fetoprotein – tumor marker	MODERATE
BAYER IMMUNO 1 SYSTEM Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Beckman Access Immunoassay System Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Beckman Coulter UniCel DxC 660i Synchron Access Clinical System Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Beckman Coulter UniCel DxC 680i Synchron Access Clinical System Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Beckman Coulter UniCel DxC 860i Synchron Access Clinical System Analyte: Alpha-fetoprotein – tumor marker	MODERATE
Beckman Coulter UniCel DxC 880i Synchron Access Clinical System Analyte: Alpha-fetoprotein – tumor marker	MODERATE
BioAutoMed ASCA Analyte: Alpha-fetoprotein – tumor marker	MODERATE

Additional Pages:

1 | 2 | 3 | 4 |